Terns Pharmaceuticals, Inc. (TERN)
NASDAQ: TERN · Real-Time Price · USD
5.64
-0.03 (-0.53%)
Aug 7, 2025, 4:00 PM - Market closed
Verve Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
493.56M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | 1.00M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TERN News
- 2 days ago - Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 days ago - Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 27 days ago - Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts - Seeking Alpha
- 6 weeks ago - Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions - GlobeNewsWire
- 2 months ago - Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences - GlobeNewsWire
- 3 months ago - Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 - GlobeNewsWire
- 3 months ago - Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference - GlobeNewsWire